Sino Biological,Inc. (SHE:301047)
91.92
-7.28 (-7.34%)
Nov 16, 2026, 4:00 PM EST
Sino Biological,Inc. Revenue
Sino Biological,Inc. had revenue of 210.98M CNY in the quarter ending September 30, 2026, with 12.83% growth. This brings the company's total for the last twelve months to 791.99M, up 19.97% year-over-year. In the year 2025, Sino Biological,Inc. had annual revenue of 699.56M with 14.00% growth. That makes Sino Biological,Inc. the 21,430th largest company in the world by revenue and 3,931st in China.
Revenue (ttm)
791.99M
Revenue Growth
+19.97%
P/S Ratio
14.12
Revenue / Employee
740.87K
Employees
1,069
Market Cap
11.18B
Revenue by Geography
- Overseas 378.50M 54.1%
- China 321.07M 45.9%
Fiscal year ended Dec 31, 2025 See the full Sino Biological,Inc. breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 699.56M | 85.89M | 14.00% |
| Dec 31, 2024 | 613.67M | -32.72M | -5.06% |
| Dec 31, 2023 | 646.39M | 71.79M | 12.49% |
| Jan 1, 2023 | 574.60M | -390.67M | -40.47% |
| Jan 1, 2022 | 965.27M | -631.02M | -39.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.34B |
| Tibet Cheezheng Tibetan Medicine | 2.23B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jinyu Bio-technology | 1.60B |
| Nanjing Vazyme Biotech | 1.56B |
| Shanghai Medicilon | 1.54B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |